COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Terveystalo Plc: Terveystalo sells the entire share capital of Porin Linnankulma Mutual Real Estate Company16/04/2018
-   
  Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting16/04/2018
-   
  Veritas Pharma Enters Into Share Purchase Agreement with 3 Carbon Extractions Inc.16/04/2018
-   
  OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting16/04/2018
-   
  Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance16/04/2018
-   
  Detroit Tigers seventh annual Pink Out the Park Sunday, May 13, brings Fans and Community Together to Raise Awareness of Breast Health16/04/2018
-   
  ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City16/04/2018
-   
  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline16/04/2018
-   
  Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting16/04/2018
-   
  Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint16/04/2018
-   
  Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting16/04/2018
-   
  Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors16/04/2018
-   
  Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA16/04/2018
-   
  Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support16/04/2018
-   
  Nova Leap Health Corp. Completes Purchase of Second Massachusetts Home Care Business and Reaches $9 Million Annualized Recurring Revenue16/04/2018
-   
  Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma16/04/2018
-   
  BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas16/04/2018
-   
  IRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30th16/04/2018
-   
  Active Biotech's rights issue over subscribed16/04/2018
Pages